



Published in final edited form as:

J Psychiatr Res. 2023 July ; 163: 195–201. doi:10.1016/j.jpsychires.2023.05.060.

***BDNF* and stress/mood-related interactions on emotional disorder symptoms, executive functioning, and deliberate self-harm**

Casey R. Guillot^{a,*}, Megan E. Kelly^a, Noah B. Phillips^a, Mei-Yi Su^a, Megan E. Douglas^b, Darian J. Poe^c, Mitchell E. Berman^d, Tiebing Liang^e

^aDepartment of Psychology, University of North Texas

^bBaylor Scott and White Institute for Rehabilitation

^cDepartment of Social Work, Psychology, and Philosophy, Texas Woman's University

^dDepartment of Psychology, Mississippi State University

^eIndiana University School of Medicine

Abstract

Some prior research has suggested that the brain-derived neurotrophic factor (*BDNF*) gene may amplify responses related to life stress (e.g., depression and anxiety) or associated with negative moods (e.g., self-harm and diminished cognitive functioning). The purpose of this study was to investigate whether stress/mood-related associations with depressive and anxiety symptoms, deliberate self-harm, and executive functioning (EF) are moderated by genotypic variations in *BDNF*rs10835210 (a relatively understudied *BDNF* polymorphism) in a nonclinical sample. As part of a larger study, European American social drinkers ($N = 132$; 43.9% female; M age = 26.0, $SD = 7.6$) were genotyped for *BDNF*rs10835210 and were administered self-report measures of subjective life stress, depressive and anxiety symptoms, and history of non-suicidal self-injury (NSSI) and behavioral measures of EF and deliberate self-harm. Results indicated that *BDNF* significantly moderated the life stress associations with depressive symptoms and NSSI, the anxious mood association with EF, and the depressed mood association with deliberate self-harm behavior. Each of these *BDNF* × stress/mood interactions were characterized by stress/mood associations that were stronger in individuals with the AA genotype (homozygous for the minor allele) than in individuals possessing a genotype that included the major allele (AC or CC). The

*Corresponding author: Department of Psychology, University of North Texas, 1155 Union Circle #311280, Denton, TX 76203-5017, USA. Tel: 940-369-8480; Fax: 940-565-4682; casey.guillot@unt.edu.

Declaration of competing interest

None.

CRediT authorship contribution statement

Casey R. Guillot: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Data Curation, Supervision, Formal Analysis, Visualization, Writing – Original Draft, Writing – Review & Editing. **Megan E. Kelly:** Supervision, Writing – Original Draft, Writing – Review & Editing. **Noah B. Phillips:** Writing – Original Draft, Writing – Review & Editing. **Mei-Yi Su:** Writing – Original Draft, Writing – Review & Editing. **Megan E. Douglas:** Supervision, Writing – Original Draft, Writing – Review & Editing. **Darian J. Poe:** Writing – Original Draft, Writing – Review & Editing. **Mitchell E. Berman:** Investigation, Resources, Funding Acquisition, Methodology, Supervision, Project Administration, Data Curation, Writing – Review & Editing. **Tiebing Liang:** Funding Acquisition, Resources, Methodology, Project Administration, Investigation, Supervision, Writing – Review & Editing.

main limitations of the present study were use of a cross-sectional design, modest sample size, and investigating only one *BDNF* polymorphism. Despite these limitations and though preliminary, current findings suggest that variations in *BDNF* may confer vulnerability to stress or mood, which may result in more adverse emotional, cognitive, or behavioral outcomes.

Keywords

brain-derived neurotrophic factor (*BDNF*) gene; depression; anxiety; executive functioning; deliberate self-harm

1. Introduction

Depressive and anxiety symptoms often co-occur (Jacobson and Newman, 2017) and have been concurrently and prospectively associated with impairments in executive functioning (EF; Zainal and Newman, 2020, 2022). Depressive and anxiety symptoms also have been associated with deliberate self-harm ranging from non-suicidal self-injury (NSSI) to suicide attempts (Favril et al., 2020; Fox et al., 2015; Victor and Klonsky, 2014). In addition, twin-based studies have evidenced that depressive and anxiety symptoms are moderately influenced by genetic factors (Gustavson et al., 2019) and display strong genetic correlations with each other as well as modest genetic correlations with EF and deliberate self-harm (Gustavson et al., 2019; Lim et al., 2022).

Given that emotional disorder symptoms (e.g., depression and anxiety) often co-occur and share genetic liability with EF deficits and deliberate self-harm, it is possible that associated genes may contribute to these conditions. One gene, called the brain-derived neurotrophic factor (*BDNF*) gene, encodes a protein that regulates synaptic plasticity, promotes dendritic growth, and plays a role in mood and cognition (Autry and Monteggia, 2012; Hing et al., 2018). Of the *BDNF* genetic polymorphisms, rs6265, a missense mutation (Val66Met), most often has been studied and across two meta-analyses has evidenced associations with panic disorder (Chen et al., 2017) and suicidal behavior (Gonzalez-Castro et al., 2017), which in both cases was an association with individuals homozygous for the minor allele (A). However, meta-analyses have not related the *BDNF*rs6265 polymorphism to major depressive disorder (Li et al., 2016) or EF (Mandelman and Grigorenko, 2012). Yet, other more recent research suggests that *BDNF* interactions with stress-related factors may be better predictors of emotional disorder symptoms, deliberate self-harm, and EF (Hing et al., 2018). In particular, meta-analyses have evidenced that the minor allele of *BDNF*rs6265 may strengthen life stress associations with depression (Hosang et al., 2014; Zhao et al., 2018), and one recent study evidenced that *BDNF*rs6265 may interact with depressive emotionality in relating to worse EF (Sanwald et al., 2020). Thus, some prior work suggests that variations in *BDNF* may increase vulnerability both to the effects of life stress on depression and to the effects of negative mood on EF.

Notably, the minor allele for another less studied *BDNF* polymorphism, rs10835210 (minor/major allele: A/C), has been associated with internalizing disorders among Chinese young adults (Meng et al., 2009; Xie et al., 2011). Also, in more recent research involving individuals of European ancestry, the AA genotype of *BDNF*rs10835210 was associated

with anxiety disorders (McGregor et al., 2018) and worse performance on the Trail Making Test (TMT; Wilkosc et al., 2016). Furthermore, *BDNF*rs10835210 interacted with childhood trauma in relating to anxiety disorders (McGregor et al., 2018) and was associated with a history of suicide attempts in patients with a substance use disorder (Icick et al., 2021). In the Icick et al. (2021) study in particular, the researchers additionally found that the minor allele (A) of *BDNF*rs10835210 was associated with higher levels of *BDNF* antisense (AS) mRNA in the frontal cortex due to the increased expression of the *BDNF-AS* gene, which inhibits *BDNF* transcription and reduces endogenous *BDNF* protein; thus, the researchers speculated that their findings may exemplify a stress-diathesis model (i.e., an adverse interaction between chronic drug use and *BDNF* gene expression), similar to what might be seen in other individuals impacted by environmental and/or neurobiological stress (e.g., individuals exposed to traumatic events or experiencing depression). Generally in accord with this idea, meta-analyses have associated stressful life events with emotional disorder symptoms (Lindert et al., 2014; March-Llanes et al., 2017) and NSSI (Liu et al., 2016), and both depression and anxiety have been implicated as risk factors in the development of deliberate self-harm behaviors (Fox et al., 2015; Liu et al., 2016; Victor and Klonsky, 2014). Taken together, the evidence above suggests that *BDNF* may moderate stress-related associations with depression, anxiety, and deliberate self-harm, and may further moderate mood-related associations with deliberate self-harm and worse EF. Except for anxiety, however, to our knowledge no prior study has investigated these possibilities in relation to *BDNF*rs10835210.

Hence, the present study investigated if stress/mood-related associations with emotional disorder symptoms, deliberate self-harm, and EF are moderated by genotypic variations in *BDNF*rs10835210 in a nonclinical sample of European Americans. We hypothesized that *BDNF* would moderate life stress associations with depression, anxiety, and deliberate self-harm (indexed by self-reported history of NSSI and performance on a behavioral task of deliberate self-harm), and we further hypothesized that *BDNF* would moderate depressed and anxious mood associations with deliberate self-harm and worse EF. More specifically, we hypothesized that these relations would be stronger in the presence of the AA genotype, given that prior research has indicated a recessive model of genetic risk may best fit the *BDNF* polymorphic data (Chen et al., 2017; Icick et al., 2021; McGregor et al., 2018; Perez-Rodriguez et al., 2017).

2. Material and methods

2.1. Participants and procedures

Participants were 132 European American social drinkers recruited from the community (Hattiesburg, MS, USA) for a larger experimental study focused on the effects of alcohol on deliberate self-harm behavior (Berman et al., 2017). The current study involves a secondary analysis of self-report and behavioral data collected as part of the larger experimental study (2006–2008) which then was combined with data from additional genotyping that was later conducted on dried blood samples (in 2015). During a preliminary phone interview, exclusion criteria included reporting a history of bipolar or psychotic disorder, past 6-month anxiety or depressive disorder, or another severe psychological problem that currently

required treatment. Potential participants were also excluded over the phone if they scored 10 or higher on the Alcohol Use Disorders Identification Test (AUDIT; Babor et al., 2001) or if they reported never having consumed alcohol (to limit the sample to social drinkers). Then as part of a subsequent laboratory session, eligible participants completed self-report measures, provided blood for genotyping, and were administered the Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999), which was included only for potential use as a covariate if there were IQ differences between genotypic groups. On a separate day, participants were administered behavioral measures, including the TMT and a laboratory task that assessed deliberate self-harm behavior (administered by trained clinical psychology doctoral students under the supervision of Dr. Mitchell E. Berman).

Although 222 participants were initially genotyped for *BDNF*rs10835210, only European American individuals were retained (to restrict the possibility of confounding due to population stratification). Of the remaining 144 individuals, 12 were excluded because of lacking self-report data, leaving a final sample of 132 European American participants (with behavioral data available for 126 participants). All participants were provided with written informed consent, which they signed after reading the document and having the study procedures fully explained to them. The University of Southern Mississippi Human Subjects Protection Review Committee approved the procedures for the larger study (Protocol 24110801, "Effects of Alcohol on Human Self-Aggressive Behavior"), which was conducted in accordance with the tenets of the Declaration of Helsinki.

2.2. Self-report measures

2.2.1. PTSD Checklist Civilian Version (PCL-C)—The 17-item PCL-C (McDonald and Calhoun, 2010; Ruggiero et al., 2003) assesses symptoms associated with post-traumatic stress disorder. However, the PCL-C is not specific to trauma, as respondents are instructed to rate how much they have been bothered during the past month by each "response to stressful life experiences" on a severity scale ranging from 1 (*not at all*) to 5 (*extremely*). Given that the PCL-C (without additional trauma assessment) is related more broadly to a person's subjective responses to stressful life experiences in general (which include but are not limited to traumatic stress), in the current study we used higher PCL-C sum scores as a proxy for more intense life stress.

2.2.2. Depression Anxiety Stress Scales (DASS)—From the 42-item version of the DASS (Lovibond and Lovibond, 1995), the DASS Depression scale (14 items) and the DASS Anxiety scale (14 items) were respectively used to assess depressive and anxiety symptoms experienced during the past week. Items are scored from 0 (*Did not apply to me at all*) to 3 (*Applied to me very much, or most of the time*), with higher sum scores indicating more depressed or anxious mood. The DASS Depression and Anxiety scales have evidenced excellent convergent and discriminant validity, both in relation to other self-report measures of depression and anxiety in nonclinical samples (Bilgel and Bayram, 2010; Crawford and Henry, 2003) and in relation to depressive and anxiety disorder diagnoses and symptom severity in clinical samples (Antony et al., 1998; Brown et al., 1997).

2.2.3. Deliberate Self-Harm Inventory (DSHI)—The 17-item DSHI (Gratz, 2001) assesses lifetime history of NSSI. Items ask if respondents have ever engaged in NSSI, such as cutting, burning, or otherwise injuring oneself (0 = *No*; 1 = *Yes*). Thus, higher DSHI sum scores indicate lifetime engagement in a larger number of different kinds of NSSI.

2.2.4. Schedule for Nonadaptive and Adaptive Personality-2 (SNAP-2)—The 28-item SNAP-2 (Clark et al., 2014) Negative Temperament scale assesses trait negative affectivity (i.e., the general tendency to experience negative mood and affectively react more strongly to minor stressors). True/false responses are scored 0 or 1, with higher sum scores indicating greater trait negative affectivity (used only as a covariate in certain analyses).

2.3. Behavioral measures

2.3.1. Trail-Making Test (TMT)—The TMT (Stern and Prohaska, 1996) is a pencil-and-paper task consisting of two parts. During Part A (TMT-A), participants must connect 25 numbers in order, but during Part B (TMT-B), participants must connect 25 numbers and letters in alphanumeric order; and completion times are recorded for each. Whereas the TMT-A is primarily a measure of visual processing speed, the TMT-B has been shown to index set shifting, a form of EF. Thus, greater TMT-A and TMT-B completion times indicate slower visual processing speed and worse EF, respectively. Though we were primarily interested in EF, we also included visual processing speed in moderation analyses.

2.3.2. Self-Aggression Paradigm (SAP)—The SAP (Berman et al., 2017) is a laboratory task that assesses deliberate self-harm behavior. During the SAP, participants are given the opportunity to self-administer electric shock each time they “lose” a trial in a “competitive reaction-time task” against a fictitious opponent (40 trials with equal wins and losses). The intensity of self-administered shock is completely under the participant’s control, including 0 (no shock), from 1 (a barely noticeable shock level) to 10 (a shock level previously judged as slightly painful), and lastly the 20-shock, which the participant is told is twice as intense as the 10-shock and “may cause minor tissue damage.” In actuality, however, the 20-shock is the same intensity as the 10-shock. Deliberate self-harm behavior was defined as the frequency of self-selected 20-shocks (range: 0–20). The validity of SAP 20-shock frequency as a measure of deliberate self-harm is supported by correlations with self-reported NSSI history and acute increases associated with serotonergic disruption and alcohol intoxication (Berman et al., 2017).

2.4. BDNF rs10835210 Genotyping

Dried blood specimens were analyzed at the Indiana Alcohol Research Center. DNA was isolated using the HotSHOT method (Truett et al., 2000). TaqMan probe was purchased from Life Sciences. Because genotyping was done by endpoint reading, thermocycling was conducted in MJ Research PTC-200 thermocyclers, and PCR products were analyzed in an ABI PRISM[®] 7300 Sequence Detection System (SDS) instrument. SDS Software 1.4.0 converted the raw data to pure dye components and plotted the results of allelic discrimination on a scatter plot of Allele X versus Allele Y.

2.5. Data Analysis

After conducting preliminary analyses (detailed below), we next conducted moderated regression analyses using Model 1 of the PROCESS macro (v4.0) for SPSS (Hayes, 2022), in which we first tested *BDNF* genotypic group (CC/CA = 0, AA = 1) as a potential moderator of life stress associations with depressive and anxiety symptoms, history of NSSI, and deliberate self-harm behavior (i.e., tested potential *BDNF* × life stress interactions). Similarly, we then tested *BDNF* genotypic group as a potential moderator of depressed and anxious mood associations with TMT (A and B) performance and deliberate self-harm behavior (i.e., tested potential *BDNF* × mood interactions). In analyses involving life stress as the predictor, trait negative affectivity was used as a covariate (to account for the possible confound of the general tendency to experience negative mood symptoms and react more strongly to daily stressors), and in analyses involving depressed or anxious mood as the predictor, co-occurring anxiety or depression was used as a covariate (to see if any depressed or anxious mood interactions are unique from other mood symptoms). For each statistically significant association, the standardized regression coefficient (β) is reported, and for each significant interaction effect, change in R^2 (or R^2 change) is reported as a measure of effect size.

To limit the possibility of Type I error, we adopted a stringent statistical significance level using the Bonferroni correction ($\alpha = .05/10 = .005$) for each of the 10 moderated regression analyses. Due to the archival nature of the current sample, we conducted a post hoc statistical power analysis (one-tailed) using G*Power 3.1.9.7 (Faul et al., 2009) with a medium effect size of .10 for f^2 (Cohen, 1988), a sample size of 126, an α of .005, and four predictors in the linear regression model, which yielded a value of .82 for power. Thus, current sample sizes (i.e., 126 for behavioral data and 132 for self-report data) were evidenced as having sufficient statistical power in detecting moderate to strong effect sizes.

3. Results

3.1. Preliminary analyses

Descriptive statistics and Cronbach's alphas for self-report scales are shown in Table 1. The genotypic frequency distribution for *BDNF* rs10835210 (43 CC, 59 CA, 30 AA) did not deviate significantly ($\chi^2 = 1.25, p = .26$) from Hardy-Weinberg equilibrium (Rodriguez et al., 2009). Fisher's exact tests and independent samples *t*-tests revealed that *BDNF* genotypic groups (CC/CA vs. AA) did not differ significantly in respect to age, sex, years of education, marital status, or WASI Full Scale IQ score (each $p > .05$). Based on the standards set by Curran et al. (1996), the score distributions for the DSHI and TMT-B were moderately to severely non-normal (skewness = 3.2–3.7; kurtosis = 10.7–18.5); however, after using a logarithmic transformation ($\text{Lg}10[\text{DSHI} + 1]$) and a square root transformation ($\text{SQRT}[\text{TMT-B}]$) to normalize the distributions of the two variables, the statistical significance of findings was not altered. Therefore, only results from analyses using raw scores are presented.

3.2. Moderated regression analyses

*BDNF*rs10835210 did not have significant main effects on depression, anxiety, NSSI history, visual processing speed, EF, or deliberate self-harm behavior (each $p > .015$). However, there were four significant *BDNF* × stress/mood interactions (detailed below and illustrated in Fig. 1 using a median split): *BDNF* × life stress interactions on depressive symptoms ($\beta = .24, p < .003, R^2$ change = .055) and history of NSSI ($\beta = .34, p < .001, R^2$ change = .11), a *BDNF* × anxious mood interaction on worse EF ($\beta = .26, p = .001, R^2$ change = .077), and a *BDNF* × depressed mood interaction on deliberate self-harm behavior ($\beta = .24, p < .004, R^2$ change = .067). No other *BDNF* × stress/mood interactions were statistically significant (each $p > .02$).

To elaborate on the significant interactions by reporting on the associated simple effects, in the presence of the *BDNF*AA genotype, life stress was strongly associated with depression ($\beta = .71, p < .001$) and NSSI history ($\beta = .94, p < .001$); anxious mood was highly related to worse EF ($\beta = .59, p < .001$); and depressed mood was highly related to deliberate self-harm behavior ($\beta = .46, p < .008$). Among the CC/CA genotypic group, however, life stress was weakly related to depression and NSSI history, and anxious and depressed mood were weakly related to EF and deliberate self-harm behavior ($\beta = -.10$ to $.13$; each $p > .20$).

4. Discussion

In the current sample, the life stress associations with self-reported depression and NSSI history, the anxious mood association with worse EF, and the depressive mood association with deliberate self-harm behavior were strengthened in the presence of the AA genotype of *BDNF*rs10835210. Though these findings are novel, they are in accord with the theory that interactions between *BDNF* gene variations and stress- or mood-related factors may alter DNA methylation and BDNF protein production, thereby increasing vulnerability to experiencing more negative emotions, cognitions, and behaviors (e.g., depressive states, thoughts of suicide, and suicide attempts; Hing et al., 2018). Hence, current findings suggest that *BDNF*rs10835210 may be a polymorphism of interest in regard to potential adverse *BDNF* × stress/mood interactions.

The present study evidenced a *BDNF* × life stress interaction on depressive symptoms. Though not specific to *BDNF*rs10835210, prior meta-analyses involving *BDNF*rs6265 similarly evidenced *BDNF* × life stress interactions on depression (Hosang et al., 2014; Zhao et al., 2018). In contrast, however, another study that included two large samples (numbering in the tens of thousands) found no significant *BDNF*rs6265 × life stress interactions on depression (Border et al., 2019). Therefore, in light of this conflicting evidence pertaining to *BDNF*rs6265, it is possible that the current *BDNF* × life stress interaction on depression was found due to investigating (a far less studied) *BDNF* polymorphism, rs10835210. Future research that genotypes rs10835210 (and other *BDNF* polymorphisms) in conjunction with assessing life stress in larger samples will be needed to better evaluate this possibility.

The current study's lack of support for a *BDNF* × life stress interaction on anxiety symptoms seemingly contradicts a previous study (McGregor et al., 2018) that evidenced

an interaction of *BDNF*rs10835210 with childhood trauma in predicting adult anxiety disorders. However, in this other study (McGregor et al., 2018), less than 20% of patients were diagnosed with panic disorder. Thus, this may help explain the discrepancy in findings given that the DASS Anxiety scale has shown the strongest associations with panic disorder (Antony et al., 1998; Brown et al., 1997). Still, the current lack of a significant *BDNF* × life stress association with anxiety symptoms (paired with the significant *BDNF* × life stress association with depression) may suggest that that *BDNF*-related emotional vulnerability is more specific to depression.

Current findings also evidenced that anxious mood was related to worse EF (as indexed by TMT-B completion time) in the presence of the AA genotype of *BDNF*rs10835210. Unlike in the previous study conducted by Wilkosc et al. (2016), however, in the current study *BDNF*rs10835210 was not related to visual processing speed (TMT-A performance). Current results may differ from Wilkosc et al. (2016) due to age being highly correlated ($r = .45$) with TMT-A performance in their study; because Wilkosc et al. (2016) did not provide information regarding whether age differed across genotypic groups, it is possible that this contributed to the discrepant findings, given that ANCOVA (which they utilized) is unable to correct mean scores for group differences in age. Lastly, the fact that current *BDNF* × anxious mood association with worse EF remained statistically significant after adjusting for co-occurring depression (together with the *BDNF* × depressed mood association with EF not being statistically significant) may suggest that *BDNF*-related cognitive vulnerability is more specific to anxiety.

In the current nonclinical sample of European Americans, lifetime history of suicide attempts was not assessed. Speaking more broadly of deliberate self-harm, however, both the *BDNF* × life stress interaction on history of NSSI and the *BDNF* × depressed mood interaction on deliberate self-harm behavior found in the current study are generally concordant with a recent study (Icick et al., 2021) that associated the AA genotype of *BDNF*rs10835210 with a history of suicide attempts in substance use disorder patients of European ancestry, which may reflect a stress-vulnerability interaction (i.e., an interaction of the neurobiological stress of chronic drug use with *BDNF* gene expression). Additionally, in the same recent study (Icick et al., 2021), the A allele of *BDNF*rs10835210 was related to gene expression associated with reduced BDNF protein levels and functioning, which provides some evidence suggestive of a biological pathway whereby *BDNF* × stress/depression interactions may exert adverse behavioral effects. On the other hand, current findings did not evidence a significant *BDNF* × anxious mood interaction on deliberate self-harm behavior. Notably though, meta-analyses have more consistently evidenced stressful life events and depressive symptomatology as risk factors for deliberate self-harm (Fox et al., 2015; Liu et al., 2016; Victor and Klonsky, 2014).

4.1. Strengths and limitations

One strength of the current investigation is the use of a multi-modal (self-report and behavioral) assessment, including a behavioral measure of deliberate self-harm (a first for a genetic association study). In addition, genotypic variation in *BDNF*rs10835210 naturally is temporally precedent to the self-report and behavioral measures used in the current

study, and thus it has a stronger case than some other (non-genetic) factors would for the potential to intensify stress-related responses (e.g., depression) and mood-related behaviors (e.g., deliberate self-harm). Nonetheless, the use of a cross-sectional design impedes our confidence in making inferences about the temporality and causality of associations. Another limitation of the current study is the use of the PCL-C (a measure of subjective responses to stressful life events) as a proxy for life stress. Some researchers would rightfully argue that “operationalizing stress based on subjective or cognitive appraisals of the stressfulness of an event...risks confounding environmental events with the individual’s underlying diathesis” (such as neuroticism; pp. 2–3, Liu et al., 2016); however, in current analyses involving the PCL-C, we did statistically adjust for trait negative affectivity in order to account for the general tendency to experience negative mood and react more strongly to stressors, which should counter at least some concern about this issue. We also acknowledge that the PCL-C as a proxy for life stress cannot distinguish the timing of stressful events (e.g., childhood vs. adulthood), and thus it would be useful for future studies to include separate assessments among adults for childhood adverse or traumatic experiences and stressful life events experienced in adulthood. Another limitation of the current study is the sole inclusion of generally healthy European American social drinkers. This occurred in part because generally healthy social drinkers were recruited as part of the larger alcohol administration study, and then only participants who reported being of European descent were retained for the current study (which was done in order to restrict the possibility of confounding due to population stratification). Still, this limits the ability to generalize current findings to other populations, and thus it would be useful for future work to attempt to replicate current findings among individuals with other racial/ethnic ancestry regardless of their drinking habits. Additional limitations of the current study include the genotyping of a single polymorphism (rs10835210) in a modestly sized sample and only testing one model of genetic inheritance (the recessive model). Future studies that employ larger samples sizes (and thus have increased statistical power) and that genotype multiple *BDNF* and other genetic polymorphisms (in addition to *BDNF* rs10835210) would allow for testing alternative genetic models as well as potential gene \times gene interactions (Li et al., 2021).

4.2. Conclusions and potential treatment implications

Despite these limitations, the current study still makes a worthwhile contribution to the literature. Some prior research has evidenced a potential role for the *BDNF* gene in increasing risk for negative stress-related emotional responses and mood-associated cognitive and behavioral responses, though most of this prior work has focused on one particular *BDNF* polymorphism (rs6265). With a relatively understudied *BDNF* polymorphism (rs10835210), the current study extends on this prior work by reporting *BDNF* \times life stress associations with self-reported depression levels and NSSI history, a *BDNF* \times anxious mood association with worse EF, and a *BDNF* \times depressed mood association with deliberate self-harm behavior. Though preliminary, current findings suggest that variations in *BDNF* may confer vulnerability to stress or mood, which may result in more adverse emotional, cognitive, and behavioral outcomes. Presently, mindfulness-based programs (Galante et al., 2021; Im et al., 2021) and transcranial magnetic stimulation (Cirillo et al., 2019; Martin et al., 2017; McClintock et al., 2020) are two promising

interventions for depression, anxiety, and associated deficits in EF. Perhaps a better future understanding of *BDNF* genetic risk and expression and BDNF brain signaling may ultimately lead to novel therapeutic interventions for emotional disorder symptoms and related behaviors (e.g., self-injurious behaviors) as well as associated impairments in cognitive functioning (Xu et al., 2021).

Funding statement

This work was supported by funding from the National Institutes of Health, including NIDA [grant L30-DA049311] and NIAAA [grants R21-AA14025 and P60-AA007611]. Neither NIDA nor NIAAA had any role in designing the study, collecting, analyzing, and interpreting the data, writing the manuscript, or deciding to submit the paper for publication.

Data availability statement

The data used to support the findings of this study are available from the corresponding author upon request.

References

- Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP, 1998. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. *Psychol. Assess* 10(2), 176–181. 10.1037/1040-3590.10.2.176
- Autry AE, Monteggia LM, 2012. Brain-derived neurotrophic factor and neuropsychiatric disorders. *Pharmacol. Rev* 64(2), 238–258. 10.1124/pr.111.005108 [PubMed: 22407616]
- Berman ME, Fanning JR, Guillot CR, Marsic A, Bullock J, Nadorff MR, McCloskey MS, 2017. Effect of alcohol dose on deliberate self-harm in men and women. *J. Consult. Clin. Psychol* 85(9), 854–861. 10.1037/ccp0000222 [PubMed: 28581318]
- Bilgel NG, Bayram N, 2010. Turkish version of the Depression Anxiety Stress Scale (DASS-42): Psychometric properties. *Nöropsikiyatri Ar ivi*. 47(2), 118–126. 10.4274/npa.5344
- Border R, Johnson EC, Evans LM, Smolen A, Berley N, Sullivan PF, Keller MC, 2019. No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. *Am. J. Psychiatry* 176(5), 376–387. 10.1176/appi.ajp.2018.18070881 [PubMed: 30845820]
- Brown TA, Chorpita BF, Korotitsch W, Barlow DH, 1997. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. *Behav. Res. Ther* 35(1), 79–89. 10.1016/S0005-7967(96)00068-X [PubMed: 9009048]
- Chen K, Wang N, Zhang J, Hong X, Xu H, Zhao X, Huang Q, 2017. Is the Val66Met polymorphism of the brain-derived neurotrophic factor gene associated with panic disorder? A meta-analysis. *Asia Pac. Psychiatry* 9(2), e12228. 10.1111/appy.12228
- Cirillo P, Gold AK, Nardi AE, Ornelas AC, Nierenberg AA, Camprodon J, Kinrys G, 2019. Transcranial magnetic stimulation in anxiety and trauma-related disorders: A systematic review and meta-analysis. *Brain Behav.* 9(6), e01284. 10.1002/brb3.1284 [PubMed: 31066227]
- Clark LA, Simms LJ, Wu KD, Casillas A, 2014. Schedule for Nonadaptive and Adaptive Personality, 2nd Edition (SNAP-2): Manual for administration, scoring, and interpretation. University of Notre Dame, South Bend, IN.
- Cohen J, 1988. *Statistical power analysis for the behavioral sciences*, 2nd ed. Routledge.
- Crawford JR, Henry JD, 2003. The Depression Anxiety Stress Scales (DASS): Normative data and latent structure in a large non-clinical sample. *Br. J. Clin. Psychol* 42(2), 111–131. 10.1348/014466503321903544 [PubMed: 12828802]
- Curran PJ, West SG, Finch JF, 1996. The robustness of test statistics to nonnormality and specification error in confirmatory factor analysis. *Psychol. Methods* 1(1), 16–29. 10.1037/1082-989X.1.1.16

- Faul F, Erdfelder E, Buchner A, Lang AG, 2009. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. *Behav. Res. Methods* 41(4), 1149–1160. 10.3758/BRM.41.4.1149 [PubMed: 19897823]
- Favril L, Yu R, Hawton K, Fazel S, 2020. Risk factors for self-harm in prison: A systematic review and meta-analysis. *Lancet Psychiatry*. 7(8), 682–691. 10.1016/S2215-0366(20)30190-5 [PubMed: 32711709]
- Fox KR, Franklin JC, Ribeiro JD, Kleiman EM, Bentley KH, Nock MK, 2015. Meta-analysis of risk factors for nonsuicidal self-injury. *Clin. Psychol. Rev* 42, 156–167. 10.1016/j.cpr.2015.09.002 [PubMed: 26416295]
- Galante J, Friedrich C, Dawson AF, Modrego-Alarcon M, Gebbing P, Delgado-Suarez I, Gupta R, Dean L, Dalgleish T, White IR, Jones PB, 2021. Mindfulness-based programmes for mental health promotion in adults in nonclinical settings: A systematic review and meta-analysis of randomised controlled trials. *PLoS Med*. 18(1), e1003481. 10.1371/journal.pmed.1003481 [PubMed: 33428616]
- Gonzalez-Castro TB, Salas-Magana M, Juarez-Rojop IE, Lopez-Narvaez ML, Tovilla-Zarate CA, Hernandez-Diaz Y, 2017. Exploring the association between BDNF Val66Met polymorphism and suicidal behavior: Meta-analysis and systematic review. *J Psychiatr. Res* 94, 208–217. 10.1016/j.jpsychires.2017.07.020 [PubMed: 28756290]
- Gratz KL, 2001. Measurement of deliberate self-harm: Preliminary data on the Deliberate Self-Harm Inventory. *J. Psychopathol. Behav. Assess* 23(4), 253–263. 10.1023/A:1012779403943
- Gustavson DE, Franz CE, Panizzon MS, Reynolds CA, Xian H, Jacobson KC, Toomey R, Lyons MJ, Kremen WS, 2019. Genetic and environmental associations among executive functions, trait anxiety, and depression symptoms in middle age. *Clin. Psychol. Sci* 7(1), 127–142. 10.1177/2167702618805075 [PubMed: 30923645]
- Hayes AF, 2022. Introduction to mediation, moderation, and conditional process analysis: A regression-based approach, 3rd ed. Guilford Press, New York.
- Hing B, Sathyaputri L, Potash JB, 2018. A comprehensive review of genetic and epigenetic mechanisms that regulate BDNF expression and function with relevance to major depressive disorder. *Am. J. Med. Genet. B Neuropsychiatr. Genet* 177(2), 143–167. 10.1002/ajmg.b.32616 [PubMed: 29243873]
- Hosang GM, Shiles C, Tansey KE, McGuffin P, Uher R, 2014. Interaction between stress and the BDNF Val66Met polymorphism in depression: A systematic review and meta-analysis. *BMC Med*. 12, 7. 10.1186/1741-7015-12-7 [PubMed: 24433458]
- Icick R, Bloch V, Prince N, Karsinti E, Lepine JP, Laplanche JL, Mouly S, Marie-Claire C, Brousse G, Bellivier F, Vorspan F, 2021. Clustering suicidal phenotypes and genetic associations with brain-derived neurotrophic factor in patients with substance use disorders. *Transl. Psychiatry* 11(1), 72. 10.1038/s41398-021-01200-5 [PubMed: 33479229]
- Im S, Stavas J, Lee J, Mir Z, Hazlett-Stevens H, Caplovitz G, 2021. Does mindfulness-based intervention improve cognitive function? A meta-analysis of controlled studies. *Clin. Psychol. Rev* 84, 101972. 10.1016/j.cpr.2021.101972 [PubMed: 33582570]
- Jacobson NC, Newman MG, 2017. Anxiety and depression as bidirectional risk factors for one another: A meta-analysis of longitudinal studies. *Psychol. Bull* 143(11), 1155–1200. 10.1037/bul0000111 [PubMed: 28805400]
- Li M, Chang H, Xiao X, 2016. BDNF Val66Met polymorphism and bipolar disorder in European populations: A risk association in case-control, family-based and GWAS studies. *Neurosci. Biobehav. Rev* 68, 218–233. 10.1016/j.neubiorev.2016.05.031 [PubMed: 27236043]
- Li X, Jiang T, Sun X, Yong X, Ma X, Liu J, 2021. The relationship between occupational stress, musculoskeletal disorders and the mental health of coal miners: The interaction between BDNF gene, TPH2 gene polymorphism and the environment. *J. Psychiatr. Res* 135, 76–85. 10.1016/j.jpsychires.2020.12.061 [PubMed: 33450468]
- Lim KX, Krebs G, Rimpfeld K, Pingault JB, Rijdsdijk FV, 2022. Investigating the genetic and environmental aetiologies of non-suicidal and suicidal self-harm: A twin study. *Psychol. Med* 52(15), 3391–3401. 10.1017/S0033291721000040

- Lindert J, von Ehrenstein OS, Grashow R, Gal G, Braehler E, Weiskopf MG, 2014. Sexual and physical abuse in childhood is associated with depression and anxiety over the life course: Systematic review and meta-analysis. *Int. J. Public Health* 59(2), 359–372. 10.1007/s00038-013-0519-5 [PubMed: 24122075]
- Liu RT, Cheek SM, Nestor BA, 2016. Non-suicidal self-injury and life stress: A systematic meta-analysis and theoretical elaboration. *Clin. Psychol. Rev* 47, 1–14. 10.1016/j.cpr.2016.05.005 [PubMed: 27267345]
- Lovibond PF, Lovibond SH, 1995. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. *Behav. Res. Ther* 33(3), 335–343. 10.1016/0005-7967(94)00075-U [PubMed: 7726811]
- Mandelman SD, Grigorenko EL, 2012. BDNF Val66Met and cognition: All, none, or some? A meta-analysis of the genetic association. *Genes Brain Behav.* 11(2), 127–136. 10.1111/j.1601-183X.2011.00738.x [PubMed: 21980924]
- March-Llanes J, Marques-Feixa L, Mezquita L, Fanas L, Moya-Higueras J, 2017. Stressful life events during adolescence and risk for externalizing and internalizing psychopathology: A meta-analysis. *Eur. Child Adolesc. Psychiatry* 26(12), 1409–1422. 10.1007/s00787-017-0996-9 [PubMed: 28502034]
- Martin DM, McClintock SM, Forster JJ, Lo TY, Loo CK, 2017. Cognitive enhancing effects of rTMS administered to the prefrontal cortex in patients with depression: A systematic review and meta-analysis of individual task effects. *Depress. Anxiety* 34(11), 1029–1039. 10.1002/da.22658 [PubMed: 28543994]
- McClintock SM, Martin DM, Lisanby SH, Alonzo A, McDonald WM, Aaronson ST, Husain MM, O'Reardon JP, Weickert CS, Mohan A, Loo CK, 2020. Neurocognitive effects of transcranial direct current stimulation (tDCS) in unipolar and bipolar depression: Findings from an international randomized controlled trial. *Depress. Anxiety* 37(3), 261–272. 10.1002/da.22988 [PubMed: 31944487]
- McDonald SD, Calhoun PS, 2010. The diagnostic accuracy of the PTSD checklist: A critical review. *Clin. Psychol. Rev* 30(8), 976–987. 10.1016/j.cpr.2010.06.012 [PubMed: 20705376]
- McGregor NW, Dimatelis JJ, Van Zyl PJ, Hemmings SMJ, Kinnear C, Russell VA, Stein DJ, Lochner C, 2018. A translational approach to the genetics of anxiety disorders. *Behav. Brain Res* 341, 91–97. 10.1016/j.bbr.2017.12.030 [PubMed: 29288745]
- Meng XF, Kou CG, Shi JP, Yu YQ, Huang YQ, 2009. [Association between polymorphism of BDNF and internalizing disorders]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 30(12), 1265–1268. 10.3760/cma.j.issn.0254-6450.2009.12.014 [PubMed: 20193311]
- Perez-Rodriguez MM, New AS, Goldstein KE, Rosell D, Yuan Q, Zhou Z, Hodgkinson C, Goldman D, Siever LJ, Hazlett EA, 2017. Brain-derived neurotrophic factor Val66Met genotype modulates amygdala habituation. *Psychiatry Res. Neuroimaging* 263, 85–92. 10.1016/j.psychres.2017.03.008 [PubMed: 28371657]
- Rodriguez S, Gaunt TR, Day IN, 2009. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. *Am. J. Epidemiol* 169(4), 505–514. 10.1093/aje/kwn359 [PubMed: 19126586]
- Ruggiero KJ, Del Ben K, Scotti JR, Rabalais AE, 2003. Psychometric properties of the PTSD Checklist-Civilian Version. *J. Trauma. Stress* 16(5), 495–502. 10.1023/A:1025714729117 [PubMed: 14584634]
- Sanwald S, Montag C, Kiefer M, 2020. Depressive emotionality moderates the influence of the BDNF Val66Met polymorphism on executive functions and on unconscious semantic priming. *J. Mol. Neurosci* 70(5), 699–712. 10.1007/s12031-020-01479-x [PubMed: 32002751]
- Stern MA, Prohaska ML, 1996. Neuropsychological evaluation of executive functioning, in: Dickstein LJ, Riba MB, Oldham JM (Eds.), *Academic Psychiatric Press Review of Psychiatry*. American Psychiatric Press, Washington, DC, pp. 243–256.
- Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML, 2000. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). *Biotechniques.* 29(1), 52–54. 10.2144/00291bm09 [PubMed: 10907076]

- Victor SE, Klonsky ED, 2014. Correlates of suicide attempts among self-injurers: A meta-analysis. *Clin. Psychol. Rev* 34(4), 282–297. 10.1016/j.cpr.2014.03.005 [PubMed: 24742496]
- Wechsler D, 1999. Wechsler Abbreviated Scale of Intelligence (WASI) Manual. The Psychological Corporation, San Antonio, TX.
- Wilkosc M, Szalkowska A, Skibinska M, Zajac-Lamparska L, Maciukiewicz M, Araszkiwicz A, 2016. BDNF gene polymorphisms and haplotypes in relation to cognitive performance in Polish healthy subjects. *Acta Neurobiol. Exp. (Wars)* 76(1), 43–52. 10.21307/ane-2017-004 [PubMed: 27102917]
- Xie B, Wang B, Suo P, Kou C, Wang J, Meng X, Cheng L, Ma X, Yu Y, 2011. Genetic association between BDNF gene polymorphisms and phobic disorders: A case-control study among mainland Han Chinese. *J. Affect. Disord* 132(1–2), 239–242. 10.1016/j.jad.2010.12.017 [PubMed: 21295349]
- Xu H, Wang J, Jing H, Ellenbroek B, Shao F, Wang W, 2021. mPFC GABAergic transmission mediated the role of BDNF signaling in cognitive impairment but not anxiety induced by adolescent social stress. *Neuropharmacology*. 184, 108412. 10.1016/j.neuropharm.2020.108412 [PubMed: 33245959]
- Zainal NH, Newman MG, 2020. Within-person increase in pathological worry predicts future depletion of unique executive functioning domains. *Psychol. Med* 51(10), 1676–1686. 10.1017/S0033291720000422 [PubMed: 32188519]
- Zainal NH, Newman MG, 2022. Depression and worry symptoms predict future executive functioning impairment via inflammation. *Psychol. Med* 52(15), 3625–3635. 10.1017/S0033291721000398
- Zhao M, Chen L, Yang J, Han D, Fang D, Qiu X, Yang X, Qiao Z, Ma J, Wang L, Jiang S, Song X, Zhou J, Zhang J, Chen M, Qi D, Yang Y, Pan H, 2018. BDNF Val66Met polymorphism, life stress and depression: A meta-analysis of gene-environment interaction. *J. Affect. Disord* 227, 226–235. 10.1016/j.jad.2017.10.024 [PubMed: 29102837]




Fig. 1.

*BDNF*rs10835210 \times stress/mood interactions (using a ± 1 *SD* split for low/high stress and less/more depressed and a ± 0.5 *SD* split for less/more anxious). PTSD Civilian Checklist (PCL-C) scores were used as a proxy for life stress, and DASS Depression and Anxiety scores indexed depressed and anxious mood. DASS = Depression Anxiety Stress Scales; DSHI = Deliberate Self-Harm Inventory; TMT-B = Trail Making Test Part B (a measure of set shifting, which is a form of executive functioning); SAP = Self-Aggression Paradigm (a measure of deliberate self-harm behavior).

Table 1

Descriptive statistics and Cronbach's alphas for self-report scales.

	Minimum	Maximum	<i>M</i> (<i>SD</i>) or %	α
Age (years)	21	54	26.0 (7.6)	
Female (sex)			43.9	
Years of education	11	22	16.6 (2.0)	
Married			17.4	
WASI Full Scale IQ	83	138	111.4 (11.2)	
SNAP-2 Negative Temperament	0	28	9.9 (6.9)	.91
PCL-C	17	77	28.7 (11.4)	.92
DASS Depression	0	22	4.0 (4.6)	.91
DASS Anxiety	0	21	4.7 (4.0)	.80
DSHI	0	7	0.5 (1.4)	.82
SAP 20-Shock Frequency	0	20	3.4 (6.2)	
TMT-A (seconds)	15.67	61.52	29.8 (7.9)	
TMT-B (seconds)	32.5	205	60.6 (23.4)	

Note. $N = 132$; sample size for the SAP and TMT is 126 due to missing data. PCL-C = PTSD Civilian Checklist (proxy for life stress); SNAP-2 = Schedule for Nonadaptive and Adaptive Personality-2; DASS = Depression Anxiety Stress Scales; DSHI = Deliberate Self-Harm Inventory; TMT = Trail Making Test; SAP = Self-Aggression Paradigm (deliberate self-harm behavior).